Using Complementary Preclinical Models to Increase Success in Biomarker Discovery for ADC ICI Combinations
Time: 11:00 am
day: Day Two
Details:
• How smart preclinical models are overcoming limitations in modelling the human immune system and tumor microenvironment
• How In vitro, ex vivo and in vivo models can provide complementary data to inform biomarker discovery and indicate patient response to ADC combination therapies.
• How tumor explant, tumor spheroid and humanized mouse models can be compared and contrasted to identify common PD and efficacy biomarkers
